Cerliponase alfa
| Clinical data | |
|---|---|
| Trade names | Brineura |
| Routes of administration | Intraventricular |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| Chemical and physical data | |
| Formula | C2657H4042N734O79S11 |
| Molar mass | ~59000 |
Cerliponase alfa, marketed as Brineura, is an enzyme replacement treatment for Batten disease, which is a form of neuronal ceroid lipofuscinosis.[1]
On 27 April 2017, it was the approved by food and drug administration to slow loss of walking ability in symptomatic children over three years old with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2). The disease is also known as tripeptidyl peptidase-1 (TPP1) deficiency.[2] Also, it was approved by European Medicines Agency on 30 May 2017.[3]
It can be given by an intraventricular route which allows significant uptake into the brain.
It was developed by BioMarin Pharmaceutical.
References
- ↑ Cerliponase alfa
- ↑ "Press Announcements - FDA approves first treatment for a form of Batten disease". www.fda.gov. Retrieved 23 July 2017.
- ↑ European Commission Approves Brineura™ (cerliponase alfa), the First Treatment for CLN2 Disease, a Form of Batten Disease and Ultra-Rare Brain Disorder in Children
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.